Table 1 The baseline characteristics between LyI- and LyI + TCGA ovarian cancer patients
From: Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1
Variable | LyI-a | LyI + b | P |
|---|---|---|---|
n | 47 | 99 | Â |
Age, mean ± SD | 58.19 ± 12.01 | 58.13 ± 10.81 | 0.976 |
Race, n (%) | Â | Â | 0.825 |
 White | 39 (83%) | 86 (86.9%) |  |
 Asian | 3 (6.4%) | 3 (3%) |  |
Black or African American | 3 (6.4%) | 5 (5.1%) | Â |
Native Hawaiian or other pacific islander | 0 (0%) | 1 (1%) | Â |
Not reported | 2 (4.3%) | 4 (4%) | Â |
FIGOc stage, n (%) | Â | Â | 0.843 |
 I-II | 6 (12.8%) | 10 (10.1%) |  |
 III-IV | 41 (87.2%) | 89 (89.9%) |  |
Vital status, n (%) | Â | Â | 0.790 |
 Alive | 27 (57.4%) | 53 (53.5%) |  |
 Dead | 20 (42.6%) | 46 (46.5%) |  |
Histological subtype, n (%) | Â | Â | 0.322 |
 Papillary serous cystadenocarcinoma | 1 (2.1%) | 0 (0%) |  |
 Serous cystadenocarcinoma | 46 (97.9%) | 99 (100%) |  |